World Hepatitis Day 2023!

World Hepatitis Day is a global initiative to raise awareness about hepatitis and its impact on millions of lives. On this important day, let’s come together to learn, educate, and advocate for prevention, testing, and treatment. Together, we can eliminate hepatitis and ensure a healthier future for all. 

Check out the website where you can find all the ways to get involved, sign the pledge, and access the campaign guidelines and resources!

2023 Theme

The theme of the campaign this year is:

Every year, more than a million lives are lost to hepatitis. We’re not waiting for change – we’re fighting to make it happen. 

WHD Communications Toolkit

Our WHD Communications Toolkit provides details on messaging, the campaign resources, example social posts and updates on other ways to get involved – like the Virtual Global Relay!

WHD Launch Webinar

Watch our webinar where we launch the 2023 campaign and discuss all the ways to get involved!

Webinars

World Hepatitis Day 2023: Community Forum – 25 July, 1pm BST

Viral hepatitis affects over 350 million people worldwide and for most, testing and treatment remain beyond reach due to several factors.

The WHD community forum gives a real insight into the many experiences, perspectives and unmet needs of people diagnosed with and living with hepatitis across the world.

The panel explore global conversations around eliminating hepatitis by 2030 and why we are not waiting for hepatitis elimination. The forum offered an open space for people living with hepatitis to share experiences and offer possible solutions to address challenges faced, as a result of the disease.

We’re not waiting – Beating hepatitis and cancer together – 27 July, 1pm BST

 

Hepatitis B virus (HBV) is an oncogenic virus that causes liver cancer at the same rate as someone who actively smokes one pack of cigarette per day.

Yet, we wait to treat HBV infected patients until they develop liver disease before initiating treatment.

The WHO ‘Best buys’ document provides recommended interventions for the prevention and control of noncommunicable diseases, and recently prevention of liver cancer through hepatitis B immunisation has been included as a recommendation.

This panel discussion and Q&A focused on the integration of the hepatitis community and hepatitis services with liver cancer and NCDs.

WHD 2023 Film

Watch our 2023 WHD campaign video!

WHD-English-10

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close